Seaport Therapeutics CEO granted new stock options

Zohar Daphne reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 05/04/2026 - 06:18 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Zohar Daphne reported acquisition or exercise transactions in this Form 4 filing.

Seaport Therapeutics, Inc. reported that Chief Executive Officer Daphne Zohar received two stock option grants on April 30, 2026 for 1,486,786 and 271,813 options to buy common stock at $18.00 per share, expiring on April 29, 2036. The options vest in forty-eight equal monthly installments after April 30, 2026, conditioned on her continued service.

Insider Trade Summary

Grant/Award: 1,758,599 shares

Grant/Award 2 txns

Insider Zohar Daphne

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	271,813	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	1,486,786	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 1,758,599 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 1,758,599 contracts (Direct)

Footnotes (1)

1. F1. The shares underlying this option shall vest in forty-eight (48) equal monthly installments following April 30, 2026, subject to the Reporting Person's continued service on each such vesting date.

Key Figures

Option grant size 1: 1,486,786 options Option grant size 2: 271,813 options Exercise price: $18.00 per share +2 more

5 metrics

Option grant size 1 1,486,786 options CEO stock option grant on April 30, 2026

Option grant size 2 271,813 options Additional CEO stock option grant on April 30, 2026

Exercise price $18.00 per share Exercise price for both CEO option grants

Expiration date April 29, 2036 Expiration for both stock option awards

Vesting schedule 48 monthly installments Vesting after April 30, 2026, subject to continued service

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, vest in forty-eight (48) equal monthly installments

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "18.0000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-04-29T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest in forty-eight (48) equal monthly installments financial

"The shares underlying this option shall vest in forty-eight (48) equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Seaport Therapeutics (SPTX) disclose for CEO Daphne Zohar?

Seaport Therapeutics disclosed that CEO Daphne Zohar received two stock option grants as compensation. These derivative awards give her rights to acquire common stock at a fixed exercise price and do not represent open-market share purchases or sales.

How many stock options were granted to the Seaport Therapeutics (SPTX) CEO?

The CEO received 1,486,786 stock options in one grant and 271,813 stock options in a second grant. Both awards relate to Seaport Therapeutics common stock and are reported as directly owned derivative securities following the transactions.

What is the exercise price and expiration date of the SPTX CEO’s new options?

Each option grant to the CEO carries an exercise price of $18.00 per share and an expiration date of April 29, 2036. This means she can buy common shares at $18.00 any time before that expiration, subject to vesting and service conditions.

How do the new Seaport Therapeutics (SPTX) options vest for the CEO?

The options vest in forty-eight equal monthly installments following April 30, 2026. Vesting is conditioned on Daphne Zohar’s continued service on each vesting date, so she earns the right to exercise portions of the grant gradually over four years.

Did the Seaport Therapeutics (SPTX) Form 4 show any insider share sales or purchases?

The Form 4 only reports stock option grants to the CEO and no open-market purchases or sales. The transactions are coded as awards of derivative securities, reflecting compensation rather than trading activity in Seaport Therapeutics common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zohar Daphne

(Last) (First) (Middle)

SEAPORT THERAPEUTICS, INC.

101 SEAPORT BLVD., FLOOR 12

(Street)

BOSTON MASSACHUSETTS 02210

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Seaport Therapeutics, Inc. [ SPTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18	04/30/2026		A		271,813		(1)	04/29/2036	Common Stock	271,813	$0	271,813	D
Stock Option (Right to Buy)	$18	04/30/2026		A		1,486,786		04/30/2026	04/29/2036	Common Stock	1,486,786	$0	1,486,786	D

Explanation of Responses:

1. The shares underlying this option shall vest in forty-eight (48) equal monthly installments following April 30, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Lana Gladstein, Attorney-in-Fact	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)